Cytiva, a biopharma research and manufacturing specialist, rolled out a new cell therapy manufacturing platform the company developed as part of a collaboration with Gilead Sciences’ Kite Pharma unit.

BioNTech has already been tinkering with its manufacturing processes in the run up to CAR-T BNT211 entering pivotal trials. Now, the German biotech has brought British company Autolus Therapeutics on ...

DUBLIN--(BUSINESS WIRE)--The "CAR T-cell Therapy - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The global market for CAR T-cell Therapy was estimated ...

Wrapping up Q3 earnings, we look at the numbers and key takeaways for the automobile manufacturing stocks, including ...

The U.S. market has proven invaluable for Japanese automakers like Toyota. According to World’s Top Exports count, nearly 20% of the money U.S. consumers spent on auto imports went to Japanese car ...

Paris-based Astraveus formed a strategic partnership with The Netherlands Center for the Clinical Advancement of Stem Cell and Gene Therapies (NecstGen) to evaluate The Lakhesys Benchtop Cell Factory™ ...

GAINESVILLE, Fla. (WCJB) - In this week’s Tech Tuesday, our partners at UF Innovate and SCAD Media spotlight Fabco-Air, a ...

SAN DIEGO--(BUSINESS WIRE)--Excellos Inc., a cell therapy contract and development manufacturing organization (CDMO) member of Blood Centers of America (BCA), today announced that it has been selected ...

Japan will be able to domestically manufacture therapeutic formulations of CAR-T treatments, a type of immunotherapy that is becoming more commonly used due to its effectiveness against relapsed or ...